Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance
Reference number: TA298
Published: 27 November 2013
Last updated: 20 May 2024

Choroidal neovascularisation (pathological myopia) - ranibizumab: final appraisal determination document

Choroidal neovascularisation (pathological myopia) - ranibizumab: final appraisal determination document

Choroidal neovascularisation (pathological myopia) - ranibizumab: final appraisal determination document
25 October 2013
(373.7 Kb 48 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 18 October 2013